INDIA
INDIA
THE DELHI HIGH COURT HELD THAT IN PATENT CASES THE REMEDIES OF REVOCATION BEFORE IPAB AND THE HIGH COURT ARE CONSISTENT WITH EACH OTHER AND CAN PROCEED SIMULTANEOUSLY.
ordered USL to stop using the Band Master Blend label as it was an imitation of PRIPL’s Master Blend label. The court rejected USL’s plea of prior adoption and use, and observed that PRIPL’s trademark for Master Blend is honest and bona fide.
USL also filed an application to restore and renew its expired trademark registration. The Registrar of Trademarks allowed USL’s application, rejecting PRIPL’s objection on the ground that statutory notice (Form O-3), which must be issued under section 25(3) of the Trademark Act, was not given to the registered proprietor, USL. An appeal was filed by PRIPL through Inttl Advocare at the Intellectual Property Appellate Board (IPAB), which stayed the order of the registrar and held that section 25(3) and 25(4) of the Trademarks Act must be read harmoniously. Section 25(4) deals with restoration of a removed trademark and prescribes a one-year timeframe (from the date of expiration of the registration) to file an application for restoration. USL’s registration expired on April 7, 2009, and the restoration application was filed on April 26, 2010. USL’s application was prima facie held as time-barred. The matter is pending for final hearing.
Whether two bodies can proceed simultaneously and decide revocation of the same patent, was determined in Dr Alloys Wobben v Yogesh Mehra & Ors. The Division Bench of the Delhi High Court delivered a judgment against Dr Wobben and his company Enercon GMBH in his action against Indian licensee Enercon India Limited (EIL). The issue raised by Dr Wobben was whether EIL was permitted to continue its revocation proceeding against Dr Wobben’s patents at
158 World Intellectual Property Review e-Digest 2012
the IPAB when it had also elected to prosecute counterclaims for revocation of the same patents in the infringement suit that was filed by Dr Wobben at the Delhi High Court. Dr Wobben filed an application seeking a stay of the IPAB proceeding until the court could decide the infringement suit.
Rejecting Dr Wobben’s pleas, the Delhi High Court held that the remedies of the IPAB and the court are consistent with each other and can proceed simultaneously.
The first-ever petition for a compulsory licence for a patented drug has been filed by Natco for Nexavar, a drug that treats kidney cancer, which is patented by Bayer in India. Natco filed the petition for the following reasons:
• After three years of its patent being granted, Bayer has not taken adequate steps to manufacture the drug in India and make full use of the invention; and
• Cancer patients who need the product Nexaver to prolong their life or improve their health are not getting the drug because it is prohibitively priced at Rs280,482 per month (approximately US$5610 per month).
Passing-off actions can be maintained by a proprietor exporting goods and not selling them in India. This was established when the Division Bench of the Bombay High Court granted relief to all exporters that do not sell their goods in India. The court interpreted
www.worldipreview.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132 |
Page 133 |
Page 134 |
Page 135 |
Page 136 |
Page 137 |
Page 138 |
Page 139 |
Page 140 |
Page 141 |
Page 142 |
Page 143 |
Page 144 |
Page 145 |
Page 146 |
Page 147 |
Page 148 |
Page 149 |
Page 150 |
Page 151 |
Page 152 |
Page 153 |
Page 154 |
Page 155 |
Page 156 |
Page 157 |
Page 158 |
Page 159 |
Page 160 |
Page 161 |
Page 162 |
Page 163 |
Page 164 |
Page 165 |
Page 166 |
Page 167 |
Page 168 |
Page 169 |
Page 170 |
Page 171 |
Page 172 |
Page 173 |
Page 174 |
Page 175 |
Page 176 |
Page 177 |
Page 178 |
Page 179 |
Page 180 |
Page 181 |
Page 182 |
Page 183 |
Page 184 |
Page 185 |
Page 186 |
Page 187 |
Page 188 |
Page 189 |
Page 190 |
Page 191 |
Page 192 |
Page 193 |
Page 194 |
Page 195 |
Page 196 |
Page 197 |
Page 198 |
Page 199 |
Page 200 |
Page 201 |
Page 202 |
Page 203 |
Page 204 |
Page 205 |
Page 206 |
Page 207 |
Page 208 |
Page 209 |
Page 210 |
Page 211 |
Page 212 |
Page 213 |
Page 214 |
Page 215 |
Page 216 |
Page 217 |
Page 218 |
Page 219 |
Page 220 |
Page 221 |
Page 222 |
Page 223 |
Page 224 |
Page 225 |
Page 226 |
Page 227 |
Page 228 |
Page 229 |
Page 230 |
Page 231 |
Page 232 |
Page 233 |
Page 234 |
Page 235 |
Page 236 |
Page 237 |
Page 238 |
Page 239 |
Page 240 |
Page 241 |
Page 242 |
Page 243 |
Page 244 |
Page 245 |
Page 246 |
Page 247 |
Page 248 |
Page 249 |
Page 250 |
Page 251 |
Page 252 |
Page 253 |
Page 254 |
Page 255 |
Page 256 |
Page 257 |
Page 258 |
Page 259 |
Page 260 |
Page 261 |
Page 262 |
Page 263 |
Page 264 |
Page 265 |
Page 266 |
Page 267 |
Page 268 |
Page 269 |
Page 270 |
Page 271